









Markets
/
Stocks
/
nasdaq-bdsx
/

Biodesix Inc

BDSX

6.340USD

-0.490-7.17%

Close 11/03, 16:00（ET）Quotes delayed by 15 min

46.47MMarket Cap

LossP/E TTM



Biodesix Inc

6.340

-0.490-7.17%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Biodesix Inc

Currency: USD Updated: 2025-11-03

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Biodesix Inc's Score

Industry at a Glance

Industry Ranking

55 / 78

Overall Ranking

287 / 4617

Industry

Healthcare Providers & Services

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 5 analysts

Buy

Current Rating

35.000

Target Price

+412.45%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Biodesix Inc Highlights

StrengthsRisks

Biodesix, Inc. (Biodesix) is a diagnostic solutions and services company. The Company develops diagnostic tests addressing clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix offers over five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung Nodule Risk Assessment testing strategy, consisting of the Nodify XL2 and the Nodify CDT tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the appropriate course of action. The blood based IQLung strategy for lung cancer patients integrates the GeneStrat targeted ddPCR test, the GeneStrat NGS test and the VeriStrat test to support treatment decisions across all stages of lung cancer. Biodesix also leverages the advanced Diagnostic Cortex artificial intelligence (AI) platform, to collaborate with biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 86.65% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 71.32M.

Overvalued

The company’s latest PE is -1.18, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 1.48M shares, decreasing 55.37% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 189.67K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-03

The company's current financial score is 6.14, which is lower than the Healthcare Providers & Services industry's average of 7.24. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 20.02M, representing a year-over-year increase of 11.68%, while its net profit experienced a year-over-year increase of 6.11%.

Score

Industry at a Glance

Previous score

6.14

Change



Financials

5.61

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.46

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.73

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.81

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.10

Key Metrics

Free cash flow

No Data

Biodesix Inc's Company Valuation

Currency: USD Updated: 2025-11-03

The company’s current valuation score is 7.21, which is higher than the Healthcare Providers & Services industry's average of 7.09. Its current P/E ratio is -1.18, which is -95.72% below the recent high of -0.05 and -307.33% above the recent low of -4.83.

Score

Industry at a Glance

Previous score

7.21

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 55/78

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-03

The company’s current earnings forecast score is 7.60, which is higher than the Healthcare Providers & Services industry's average of 7.56. The average price target for Biodesix Inc is 35.00, with a high of 40.00 and a low of 30.00.

Score

Industry at a Glance

Previous score

7.60

Change

Support & Resistance

No Data

Analyst Rating

Based on 5 analysts

Buy

Current Rating

35.000

Target Price

+412.45%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Biodesix Inc

BDSX

CVS Health Corp

CVS

HCA Healthcare Inc

HCA

Teladoc Health Inc

TDOC

Tenet Healthcare Corp

THC

Universal Health Services Inc

UHS

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-03

The company’s current price momentum score is 6.93, which is equal to the Healthcare Providers & Services industry's average of 6.93. Sideways: Currently, the stock price is trading between the resistance level at 7.75 and the support level at 5.38, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.31

Change

-0.38

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(4)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.372

Neutral

RSI(14)

48.614

Neutral

STOCH(KDJ)(9,3,3)

48.121

Neutral

ATR(14)

0.696

High Vlolatility

CCI(14)

-43.932

Neutral

Williams %R

74.070

Sell

TRIX(12,20)

0.083

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

6.566

Sell

MA10

6.547

Sell

MA20

6.914

Sell

MA50

5.281

Buy

MA100

2.813

Buy

MA200

1.737

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-03

The company’s current institutional recognition score is 3.00, which is lower than the Healthcare Providers & Services industry's average of 6.96. The latest institutional shareholding proportion is 20.13%, representing a quarter-over-quarter decrease of 76.89%. The largest institutional shareholder is The Vanguard, holding a total of 189.67K shares, representing 2.59% of shares outstanding, with 1.56% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Schuler (Jack W)

2.13M

+8.14%

Kennedy (Lawrence T Jr.)

1.27M

+0.42%

Telemark Asset Management, LLC

414.13K

Patience (John)

373.31K

+0.31%

Birchview Capital, LP

286.81K

The Vanguard Group, Inc.

Star Investors

189.67K

-0.79%

Strobeck (Matthew W)

152.98K

Perceptive Advisors LLC

108.69K

Monashee Investment Management, LLC

100.00K

-50.62%

Industrial Development Funding LLC

94.39K

Risk Assessment

Currency: USD Updated: 2025-11-03

The company’s current risk assessment score is 1.15, which is lower than the Healthcare Providers & Services industry's average of 5.45. The company's beta value is 0.97. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.